Table 1 The characteristics of the included studies
Study ID | Study design | Country | Case | Sex (M/F*) | Age (year) | Affected hand (L/R*) | Follow-up (months) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AWP | USO | AWP | USO | AWP | USO | AWP | USO | AWP | USO | |||
Bernstein 2004 | RCS | USA | 11 | 16 | 6/5 | 8/8 | 24–61 | 19–65 | UA* | UA | 7–61 | 7–58 |
Constantine 2000 | RCS | USA | 11 | 11 | 5/6 | 3/8 | 46 | 35 | UA | UA | 26 | 46 |
Auzias 2020 | RCS | France | 24 | 9 | UA | UA | 44.4 ± 12 | 39.1 ± 4 | UA | UA | 55 + − 4 | 103 ± 8 |
Oh 2018 | RCS | Korea | 19 | 23 | 8/11 | 9/14 | 53.8 ± 7.0 | 53.5 ± 6.6 | 14/5 | 10/13 | 34.6 ± 12.0 | 36.2 ± 11.6 |
Teng 2020 | RCT | China | 19 | 23 | 13/6 | 16/7 | UA | UA | 7/12 | 8/15 | 14.61 ± 2.19 | 14.61 ± 2.19 |
Chen 2020 | RCS | China | 22 | 23 | 13/9 | 13/10 | 38.4 ± 9.5 | 37.3 ± 7.1 | 6/16 | 6/17 | 13.7 | 14.3 |
Smet 2014 | RCS | Belgium | 12 | 28 | 8/4 | 22/6 | 31–66 | 16–61 | UA | UA | UA | UA |
Afifi 2022 | RCT | Egypt | 30 | 30 | 18/12 | 26/4 | UA | UA | 4/26 | 10/20 | 22 ± 5.7 | 21.1 ± 5.3 |